Compare Stocks: LKFT, MIRM, CGON, and XENE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.42 +1.4%	$66.58	$23.65 ▼ $77.00	$6.30B	0.23	940,442 shs	922,743 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$26.08 -1.4%	$28.74	$26.03 ▼ $37.78	$1.74B	0.27	174,518 shs	319,781 shs
MIRM Mirum Pharmaceuticals	$105.79 +1.4%	$110.46	$50.25 ▼ $130.00	$6.36B	0.52	595,946 shs	856,163 shs
XENE Xenon Pharmaceuticals	$64.30 +0.5%	$59.87	$32.78 ▼ $72.66	$6.19B	0.62	1.12 million shs	609,513 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+1.43%	+4.77%	+4.56%	+4.68%	+168.82%
LKFT Lakefront Biotherapeutics American Depositary Shares	-1.40%	-5.92%	-14.07%	-5.95%	-20.95%
MIRM Mirum Pharmaceuticals	+1.40%	-1.41%	-13.22%	+2.78%	+104.07%
XENE Xenon Pharmaceuticals	+0.45%	+1.90%	+6.21%	+14.82%	+86.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.42 +1.4%	$66.58	$23.65 ▼ $77.00	$6.30B	0.23	940,442 shs	922,743 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$26.08 -1.4%	$28.74	$26.03 ▼ $37.78	$1.74B	0.27	174,518 shs	319,781 shs
MIRM Mirum Pharmaceuticals	$105.79 +1.4%	$110.46	$50.25 ▼ $130.00	$6.36B	0.52	595,946 shs	856,163 shs
XENE Xenon Pharmaceuticals	$64.30 +0.5%	$59.87	$32.78 ▼ $72.66	$6.19B	0.62	1.12 million shs	609,513 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+1.43%	+4.77%	+4.56%	+4.68%	+168.82%
LKFT Lakefront Biotherapeutics American Depositary Shares	-1.40%	-5.92%	-14.07%	-5.95%	-20.95%
MIRM Mirum Pharmaceuticals	+1.40%	-1.41%	-13.22%	+2.78%	+104.07%
XENE Xenon Pharmaceuticals	+0.45%	+1.90%	+6.21%	+14.82%	+86.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.71	Moderate Buy	$81.73	12.85% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.25	Hold	$34.33	31.65% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$143.40	35.55% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.20	20.06% Upside

Current Analyst Ratings Breakdown

Latest LKFT, MIRM, CGON, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/29/2026	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
7/17/2026	CGON CG Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/10/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Equal Weight	$30.00
7/7/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$142.00 ➝ $148.00
7/6/2026	XENE Xenon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	MIRM Mirum Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$115.00 ➝ $125.00
6/23/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
6/15/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/15/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/15/2026	MIRM Mirum Pharmaceuticals	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$146.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,581.05	N/A	N/A	$9.33 per share	7.76
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.65	$0.72 per share	36.43	$47.57 per share	0.55
MIRM Mirum Pharmaceuticals	$521.31M	12.37	$0.05 per share	2,046.53	$6.12 per share	17.29
XENE Xenon Pharmaceuticals	$7.50M	828.78	N/A	N/A	$7.53 per share	8.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.33	N/A	N/A	N/A	N/A	-23.33%	-22.24%	8/7/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	8/10/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$13.61	N/A	813.77	N/A	-140.24%	-11.28%	-3.84%	N/A
XENE Xenon Pharmaceuticals	-$345.91M	-$4.70	N/A	N/A	N/A	N/A	-49.23%	-46.42%	8/6/2026 (Estimated)

Latest LKFT, MIRM, CGON, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	N/A	N/A	N/A	$7.29 million	N/A
8/7/2026	Q2 2026	CGON CG Oncology	-$0.6642	N/A	N/A	N/A	$0.36 million	N/A
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.14	N/A	N/A	N/A	$1.67 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
5/8/2026	Q1 2026	CGON CG Oncology	-$0.58	-$0.71	-$0.13	-$0.71	$0.45 million	$1.08 million
5/7/2026	Q1 2026	XENE Xenon Pharmaceuticals	-$1.17	-$1.17	N/A	-$1.17	$1.36 million	N/A
5/6/2026	Q1 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$1.27	$0.25	+$1.52	$0.25	$11.26 million	$8.75 million
5/6/2026	Q1 2026	MIRM Mirum Pharmaceuticals	-$0.75	-$13.43	-$12.68	-$13.43	$148.21 million	$159.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	31.30	31.25
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	30.48	30.30
MIRM Mirum Pharmaceuticals	1.28	2.09	1.99
XENE Xenon Pharmaceuticals	N/A	27.79	27.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
MIRM Mirum Pharmaceuticals	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
MIRM Mirum Pharmaceuticals	8.32%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	88.20 million	83.97 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
MIRM Mirum Pharmaceuticals	140	60.98 million	55.91 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

LKFT, MIRM, CGON, and XENE Headlines

Recent News About These Companies

Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co.

August 4 at 4:40 AM | marketbeat.com

Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday

August 2, 2026 | marketbeat.com

Lazard Asset Management LLC Sells 27,908 Shares of Xenon Pharmaceuticals Inc. $XENE

August 2, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Raised to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | globenewswire.com

Janus Henderson Group PLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

July 31, 2026 | marketbeat.com

Renaissance Technologies LLC Takes $17.47 Million Position in Xenon Pharmaceuticals Inc. $XENE

July 31, 2026 | marketbeat.com

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30, 2026 | financialpost.comF

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30, 2026 | globenewswire.com

Stempoint Capital LP Sells 207,850 Shares of Xenon Pharmaceuticals Inc. $XENE

July 30, 2026 | marketbeat.com

26,186 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by SummitTX Capital L.P.

July 30, 2026 | marketbeat.com

Redmile Group LLC Purchases 128,792 Shares of Xenon Pharmaceuticals Inc. $XENE

July 29, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Acquired by ADAR1 Capital Management LLC

July 29, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE is Rock Springs Capital Management LP's 9th Largest Position

July 28, 2026 | marketbeat.com

Eversept Partners LP Lowers Holdings in Xenon Pharmaceuticals Inc. $XENE

July 28, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. $XENE Shares Purchased by Swiss National Bank

July 28, 2026 | marketbeat.com

64,563 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Castleark Management LLC

July 28, 2026 | marketbeat.com

Orbimed Advisors LLC Acquires 612,771 Shares of Xenon Pharmaceuticals Inc. $XENE

July 27, 2026 | marketbeat.com

Octagon Capital Advisors LP Purchases Shares of 490,000 Xenon Pharmaceuticals Inc. $XENE

July 27, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT, MIRM, CGON, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

$72.42 +1.02 (+1.43%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$71.74 -0.67 (-0.93%)

As of 04:30 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$26.08 -0.37 (-1.40%)

As of 08/5/2026 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Mirum Pharmaceuticals NASDAQ:MIRM

$105.79 +1.46 (+1.40%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$86.33 -19.46 (-18.39%)

As of 04:01 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Xenon Pharmaceuticals NASDAQ:XENE

$64.30 +0.29 (+0.45%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$64.52 +0.22 (+0.33%)

As of 04:09 AM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LKFT, MIRM, CGON, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LKFT, MIRM, CGON, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LKFT, MIRM, CGON, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT, MIRM, CGON, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Mirum Pharmaceuticals NASDAQ:MIRM

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LKFT, MIRM, CGON, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LKFT, MIRM, CGON, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LKFT, MIRM, CGON, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LKFT, MIRM, CGON, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Mirum Pharmaceuticals NASDAQ:MIRM

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools